• Benign Prostatic Hyperplasia
  • Hormone Therapy
  • Genomic Testing
  • Next-Generation Imaging
  • UTUC
  • OAB and Incontinence
  • Genitourinary Cancers
  • Kidney Cancer
  • Men's Health
  • Pediatrics
  • Female Urology
  • Sexual Dysfunction
  • Kidney Stones
  • Urologic Surgery
  • Bladder Cancer
  • Benign Conditions
  • Prostate Cancer

Potomac Urology Center presents largest single center study of Aquablation

Feature
Video

"In our commercial all-comers cohort of patients undergoing Aquablation, efficacy was similar to and safety was improved compared to the WATER I and WATER II clinical trials," says Shawn H. Marhamati, MD, MS.

In this video, Shawn H. Marhamati, MD, MS, shares data from the study, “Aquablation Case Series of 812 Consecutive Men with LUTS due to BPH,” which was presented at the 2024 American Urological Association Annual Meeting in San Antonio, Texas. Marhamati is a urologist at Potomac Urology in Northern Virginia.

Video Transcript:

My name is Dr. Shawn Marhamati with Potomac Urology Center in Northern Virginia. We have presented what is to our knowledge the largest single center real-world Aquablation experience to date. We have performed Aquablation starting in 2018 on 812 consecutive patients. Our mean gland size was 76.5 grams, with a range of 22 to 263 grams. Preoperatively, 14.4% of our patients were in preoperative retention, with 94% of them going on to pass their trial of voids. Fifty-three percent of our cases were done as day cases. Our mean procedure time, that is from TRUS insertion to Foley insertion, was just under 55 minutes. In terms of outcomes data, our uroflow improvements were nearly 11 milliliters per second at 3 months postoperatively. Our IPSS scores improved from a baseline of 20.5 to 7 or less than 6 months and beyond. Just 1.6% of our patients required surgical retreatment; the majority of those were earlier on in our series. In terms of safety data, our all-in Clavien-Dindo 3 and above complication rate was just 3.2%, which compared favorably to the WATER I and WATER II clinical trials.

In our commercial all-comers cohort of patients undergoing Aquablation, efficacy was similar to and safety was improved compared to the WATER I and WATER II clinical trials. This was driven by significant reduction in bleeding risk due to the standardization of focal bladder neck cautery. As a result of our experience with same-day Aquablation, we've been granted the first trial in the US of ambulatory surgery center Aquablation, which is currently ongoing.

This transcription has been edited for clarity.

Related Videos
Blur image of hospital corridor | Image Credit: © whyframeshot - stock.adobe.com
Gamal M. Ghoniem, MD, FACS, ABU/FPMRS, gives an answer during a video interview
Edward M. Schaeffer, MD, PhD, answers a question during a Zoom video interview
Zhina Sadeghi, MD, answers a question during a video interview
Stephanie Gleicher, MD, answers a question during a Zoom video interview
Human kidney cross section on scientific background | © Crystal light - stock.adobe.com
Mature woman with her doctor | Image Credit: © pucko_ns - stock.adobe.com
Related Content
© 2024 MJH Life Sciences

All rights reserved.